Beta-cell rejuvenation with thiazolidinediones.


Type 2 diabetes mellitus manifests in an insulin-resistant individual when pancreatic beta-cells are unable to produce sufficient insulin to overcome insulin resistance in the muscles and liver. There is a growing body of evidence that the thiazolidinedione (TZD) class of antidiabetic agents rejuvenates beta-cells and improves their function. When combination therapy with a sulfonylurea drug and metformin fails, treatment with a TZD increases C-peptide concentrations, reflecting improvement in beta-cell function. Further evidence of TZD-induced preservation of beta-cell function is documented by the findings of several recent trials in diabetes prevention. This apparent ability of TZDs to rejuvenate beta-cells, in addition to improving insulin resistance and glycemic control, is a compelling reason to use these agents as initial therapy for type 2 diabetes.


Citations per Year

234 Citations

Semantic Scholar estimates that this publication has 234 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bell2003BetacellRW, title={Beta-cell rejuvenation with thiazolidinediones.}, author={David S. H. Bell}, journal={The American journal of medicine}, year={2003}, volume={115 Suppl 8A}, pages={20S-23S} }